Literature DB >> 8681380

An Mll-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: a method to create fusion oncogenes.

J Corral1, I Lavenir, H Impey, A J Warren, A Forster, T A Larson, S Bell, A N McKenzie, G King, T H Rabbitts.   

Abstract

Homologous recombination in embryonal stem cells has been used to produce a fusion oncogene, thereby mimicking chromosomal translocations that frequently result in formation of tumor-specific fusion oncogenes in human malignancies. AF9 sequences were fused into the mouse Mll gene so that expression of the Mll-AF9 fusion gene occurred from endogenous Mll transcription control elements, as in t(9;11) found in human leukemias. Chimeric mice carrying the fusion gene developed tumors, which were restricted to acute myeloid leukemias despite the widespread activity of the Mll promoter. Onset of perceptible disease was preceded by expansion of ES cell derivatives in peripheral blood. This novel use of homologous recombination formally proves that chromosomal translocations contribute to malignancy and provides a general strategy to create fusion oncogenes for studying their role in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8681380     DOI: 10.1016/s0092-8674(00)81269-6

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  137 in total

1.  MLL and CREB bind cooperatively to the nuclear coactivator CREB-binding protein.

Authors:  P Ernst; J Wang; M Huang; R H Goodman; S J Korsmeyer
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Creating a transloxation. Engineering interchromosomal translocations in the mouse.

Authors:  G Testa; A F Stewart
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

3.  Functional analysis of the leukemia protein ELL: evidence for a role in the regulation of cell growth and survival.

Authors:  R W Johnstone; M Gerber; T Landewe; A Tollefson; W S Wold; A Shilatifard
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms.

Authors:  M Ladanyi
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

5.  The MT domain of the proto-oncoprotein MLL binds to CpG-containing DNA and discriminates against methylation.

Authors:  Marco Birke; Silke Schreiner; María-Paz García-Cuéllar; Kerstin Mahr; Fritz Titgemeyer; Robert K Slany
Journal:  Nucleic Acids Res       Date:  2002-02-15       Impact factor: 16.971

6.  MSF (MLL septin-like fusion), a fusion partner gene of MLL, in a therapy-related acute myeloid leukemia with a t(11;17)(q23;q25).

Authors:  M Osaka; J D Rowley; N J Zeleznik-Le
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-25       Impact factor: 11.205

7.  The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.

Authors:  Benjamin Mizukawa; Eric O'Brien; Daniel C Moreira; Mark Wunderlich; Cindy L Hochstetler; Xin Duan; Wei Liu; Emily Orr; H Leighton Grimes; James C Mulloy; Yi Zheng
Journal:  Blood       Date:  2017-08-04       Impact factor: 22.113

Review 8.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis.

Authors:  Ali Shilatifard
Journal:  Annu Rev Biochem       Date:  2012       Impact factor: 23.643

9.  Grist for the MLL: how do MLL oncogenic fusion proteins generate leukemia stem cells?

Authors:  Tim C P Somervaille; Michael L Cleary
Journal:  Int J Hematol       Date:  2010-05-08       Impact factor: 2.490

Review 10.  Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects.

Authors:  David P Harper; Peter D Aplan
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.